Discussion Our analysis of Truveta Data reveals notable trends in the prescribing patterns of AOM semaglutide compared to AOM liraglutide, among adolescents aged 12 to 17 years between January 2021 and March 2025
Future direction: Multi target combination and cell therapy To overcome current limitations, the "central plan" intervention for GLP-1RA is moving towards the following directions: Multi target agonist development GLP-1/GIP/GCGR triple target agonists (such as Retatrutide) have entered phase III clinical trials, and their weight loss effect is expected to reach 22% -24%
Landreth, G., Jiang, Q., Mandrekar, S
Keep yourself (and your pee) healthy Peeing is important its how fluid waste leaves our body, and it keeps many of our other systems working smoothly
While alternative routes, including topical, implantable and microneedle patches, also exist, studies suggest that engineering GLP1 analogs to resist enzymatic breakdown extends halflife and enhances therapeutic effect
Lower inflammation burden Excess body fat contributes to systemic inflammation
